TYK2 Inhibitors for the Management of Plaque Psoriasis:
Which of Your Patients May Benefit?
Podcast 1: Post-test
Questions marked with a
*
are required
100%
Contact Information
First Name
Last Name
Email Address
Credentials/Degree (MD, DO, RN, etc.)
Date of Participation
Month
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Day
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Year
2018
2019
2020
2021
2022
2023
2024
2025
Deucravacitinib has shown a _____ fold selectively for _______ over other JAKs?
25:JAK1
50:JAK2
75:TYK2
100: TYK2
A 40 year old male has psoriasis on 25% of his body. He has lost efficacy to multiple biologics. What would be a possible treatment option for him?
Bimekizumab
Tildrakizumab
Risankizumab
Deucravacitinib
What is your job role?
Dermatologist
Physician Assistant
Nurse Practitioners
Pharmacists
Other
What is your type of practice?
Hospital
Community/Private
Academic
Clinic
Other
How many years have you been in practice?
Less than 5
5 to 9
10 to 15
More than 15
N/A
Please estimate the number of patients with Plaque Psoriasis that you treat each month:
1 to 10
11 to 25
26 to 50
51 to 75
More than 75
N/A
Were the following learning objectives met?
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
Interpret results from studies assessing treatment options with different mechanisms of action for patients with moderate-to-severe plaque psoriasis
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
Identify patients with moderate-to-severe plaque psoriasis who may benefit from a TYK2 inhibitor
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
Please rate your confidence in your ability to evaluate data regarding targeted treatments for patients with Plaque Psoriasis on a scale of 1 to 5, where 1 means "not confident at all," and 5 means "very confident."
1
2
3
4
5
Confidence
1
2
3
4
5
As a result of this course, I will likely make changes to my practice.
Yes
No
N/A
If YES, in which of the following categories?
(Please check all that apply)
Use of TYK2 inhibitor for the treatment of plaque psoriasis
Identify patients who may benefit from TYK2 inhibitor treatment
Monitor alternate treatment options for patients with moderate to severe plaque psoriasis
Patient Communication/ Education
In particular, as a result of this course, I will be more likely to implement the following changes:
(Please check all that apply)
Utilize TKT2 inhibitors for the treatment of patients with moderate to severe plaque psoriasis
Adopt strategies for the management of TKT2 inhibitor-specific adverse events when treating patients with plaque psoriasis
Make informed decisions about which TYK2 inhibitors to prescribe in patients based on their efficacy and safety profiles
Make informed decisions about the utility of various novel and upcoming treatments in the management of treatment in patients with plaque psoriasis
Additionally, I will change:
What barriers may prevent/inhibit changes in practice recommended in this activity?
(Please check all that apply.)
:
Cost
Time
# of Patients
Access/Availability
Patient Understanding
Compliance
Other
Please evaluate this activity as a whole.
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
The learning format was interactive and engaging
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
The content was pertinent to my professional needs
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
The activity will ultimately benefit patient care
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
I would recommend this activity to colleagues
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Do you feel a commercial product, device, or service was inappropriately promoted in this educational activity?
Yes
No
If YES, please comment:
What was the most effective aspect(s) of this learning activity?
(Please check all that apply.)
:
Faculty Expertise
Educational Format
Visual Aids
Content
Case Studies
Other
Do you have suggestions for improving the session or for topics for future activities?
(Please check all that apply.)
:
New and Emerging Therapies
Management of Adverse Events Associated with Novel Therapies
Patient Education/Communication
Other Treatment Modalities
Coordination of Care
Other
Please evaluate the faculty: Jerry Bagel, MD
Poor
Fair
Average
Good
Excellent
Med Learning Group has my permission to fax or email information to me about further programs.
Yes
No
At times, MLG partners to conduct educational outcomes analyses on treatment and/or diagnosis behavior that are all deidentified and rolled-up across all learners
I give permission to use my deidentified outcomes data for further research related to the impact of CME
I decline the use of my deidentified outcomes data for further research related to the impact of CME
Any additional comments are welcome below.
Done
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close
drag_indicator
highlight_off